Hironobu Ohmatsu

ORCID: 0000-0001-5423-4230
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Medical Imaging Techniques and Applications
  • Neuroendocrine Tumor Research Advances
  • Advanced X-ray and CT Imaging
  • AI in cancer detection
  • Medical Image Segmentation Techniques
  • Cancer therapeutics and mechanisms
  • Cancer Cells and Metastasis
  • Colorectal Cancer Treatments and Studies
  • Medical Imaging and Pathology Studies
  • Cancer Treatment and Pharmacology
  • Lymphatic System and Diseases
  • Atomic and Subatomic Physics Research
  • Brain Tumor Detection and Classification
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Medical Imaging and Analysis
  • Gastric Cancer Management and Outcomes
  • Cancer Diagnosis and Treatment
  • Myasthenia Gravis and Thymoma
  • Gyrotron and Vacuum Electronics Research
  • Cancer Genomics and Diagnostics
  • Chronic Obstructive Pulmonary Disease (COPD) Research

National Cancer Center Hospital East
2009-2018

Japan Clinical Cancer Research Organization
2015

Eli Lilly (United States)
2014

Ministry of Health Labour and Welfare
2014

National Cancer Centre Japan
1997-2012

Teikyo University
2008-2009

Tokushima University
1995-2009

Kyoto University Hospital
2009

Tokushima University Hospital
2009

Saiseikai Nakatsu Hospital
2008

PURPOSE: To compare low-dose spiral computed tomography (CT) with radiography of the chest for screening and detection small peripheral lung cancers in a high-risk population. MATERIALS AND METHODS: Posteroanterior lateral radiographs CT scans were obtained twice year from September 1993 to April 1995 1,369 individuals (a total 3,457 examinations) who at high risk cancer. Low-dose parameters 120 kvP, 50 mA, 10-mm collimation, 2:1 pitch. RESULTS: Peripheral cancer was detected 15 examinations...

10.1148/radiology.201.3.8939234 article EN Radiology 1996-12-01

PURPOSE: Because efficacy of lung cancer screening using chest x-ray is controversial and insufficient, other modalities need to be developed. To provide data on performance low-dose helical computed tomography (CT) scanning its in terms survival, a one-arm longitudinal project was conducted. PATIENTS AND METHODS: A total 1,611 asymptomatic patients aged 40 79 years, 86% with smoking history, were screened by CT scan, x-ray, 3-day pooled sputum cytology 6-month interval. RESULTS: At initial...

10.1200/jco.2002.20.4.911 article EN Journal of Clinical Oncology 2002-02-15

Objectives SN-38, an active metabolite of irinotecan, is detoxified by glucuronidation with UGT1A isoforms, 1A1, 1A7, 1A9, and 1A10. The pharmacogenetic information on haplotypes covering all these isoforms important for the individualized therapy irinotecan. Associations between pharmacokinetics/pharmacodynamics irinotecan were investigated to identify markers. Methods area under concentration curve ratio (SN-38 glucuronide/SN-38) or toxicities analyzed in 177 Japanese cancer patients...

10.1097/fpc.0b013e328014341f article EN Pharmacogenetics and Genomics 2007-07-01

IntroductionThe information regarding therapeutically relevant genomic alterations in small cell lung cancer (SCLC) is not well developed. We analyzed the SCLC genome using an integrative approach to stratify targetable alterations.MethodsWe performed whole exon sequencing (n = 51) and copy number analysis =47) on surgically resected tumors matched normal tissue samples from treatment-naive Japanese patients.ResultsThe demographics of 51 patients included this study were as follows: median...

10.1097/jto.0000000000000250 article EN cc-by-nc-nd Journal of Thoracic Oncology 2014-08-14

Abstract Purpose: Although large-cell neuroendocrine carcinoma (LCNEC) of the lung shares many clinical characteristics with small-cell cancer (SCLC), little is known about its molecular features. We analyzed LCNECs to identify biologically relevant genomic alterations. Experimental Design: performed targeted capture sequencing all coding exons 244 cancer-related genes on 78 LCNEC samples [65 surgically resected cases, including 10 combined non–small cell (NSCLC) types separately, and...

10.1158/1078-0432.ccr-16-0355 article EN Clinical Cancer Research 2016-08-10

Abstract Purpose: The biologic characteristics of microenvironmental constituents, especially cancer-associated fibroblasts (CAF), can be key regulators the cellular sensitivity to molecular-targeted therapy. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) have marked therapeutic effects against non–small cell lung cancer (NSCLC) with EGFR mutations, but some patients exhibited primary resistance EGFR-TKIs. We recently reported that podoplanin-positive are associated a...

10.1158/1078-0432.ccr-14-0846 article EN Clinical Cancer Research 2014-11-12

Objective: To clarify the progression of focal pure ground-glass opacity (pGGO) detected by low-dose helical computed tomography (CT) screening for lung cancer. Methods: A total 15,938 CT examinations were performed in 2052 participants project, and 1566 them judged to have yielded abnormal findings requiring further examination. Patients with peripheral nodules exhibiting pGGO at time first thin-section examination confirmed histologically after follow-up more than 6 months enrolled current...

10.1097/00004728-200401000-00003 article EN Journal of Computer Assisted Tomography 2004-01-01

Purpose We conducted a phase II study of single agent treatment with gefitinib in chemotherapy-naïve patients advanced non–small-cell lung cancer (NSCLC) to assess its efficacy and toxicity. Patients Methods received 250 mg doses daily. Administration was terminated if partial response (PR) not achieved within 8 weeks or tumor reduction observed 4 weeks. In these cases, platinum-based doublet chemotherapy given as salvage treatment. evaluated mutation status the epidermal growth factor...

10.1200/jco.2005.02.5825 article EN Journal of Clinical Oncology 2005-12-28

Journal Article Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion Get access Yuichiro Ohe, Ohe * Department Internal Medicine, National Cancer Center HospitalTokyo, Japan *Correspondence to : M.D., Hospital, 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104,Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Yasutsuna Sasaki, Sasaki Tetsu Shinkai, Shinkai Kenji Eguchi, Eguchi Tomohide Tamura, Tamura Akira Kojima, Kojima Hiroshi Kunikane,...

10.1093/jnci/84.12.972 article EN JNCI Journal of the National Cancer Institute 1992-06-17

Platinum-based two-drug combination chemotherapy has been standard of care for patients with advanced nonsmall-cell lung cancer (NSCLC). The primary aim was to compare overall survival (OS) NSCLC between the two regimens. Secondary end points included progression-free (PFS), response, safety, and quality life (QoL).Patients previously untreated stage IIIB or IV NSCLC, an Eastern Cooperative Oncology Group performance status 0-1 adequate organ function were randomized receive either oral S-1...

10.1093/annonc/mdv190 article EN cc-by-nc Annals of Oncology 2015-04-24

ObjectiveMagnesium supplementation has been reported to have a nephroprotective effect on cisplatin-induced renal dysfunction, but little evidence exists regarding the of magnesium preloading before cisplatin administration. We started include (8 mEq) in cisplatin-containing treatment regimens January 2011. The aim present study was evaluate whether reduces nephrotoxicity.

10.1093/jjco/hyu004 article EN Japanese Journal of Clinical Oncology 2014-02-05

PURPOSE: To clarify the computed tomographic (CT) findings and progression of minute lung cancers that were missed at initial spiral CT screening but later detected. MATERIALS AND METHODS: The from seven patients with cancer was reviewed. Retrospective findings, time to detection, cell type, pathologic stage evaluated. RESULTS: Minute early included a nodule among shadows old tuberculosis (n = 2), faint high attenuation in center 1), an increase just adjacent axial peripheral pulmonary...

10.1148/radiology.212.1.r99jn1461 article EN Radiology 1999-07-01

Thymic carcinoma is a rare neoplasm that often disseminates or metastasizes. The role of chemotherapy in treating this malignancy unclear. purpose the current study was to determine efficacy and tolerability weekly regimen consisting cisplatin, vincristine, doxorubicin, etoposide (CODE) for treatment advanced thymic carcinoma.The authors retrospectively reviewed 18 patients with who were treated between 1996 2002. Twelve these had unresectable diseases received according CODE regimen....

10.1002/cncr.11606 article EN Cancer 2003-07-17

Characterization of pulmonary nodules plays a significant role in the differential diagnosis lung cancer. This paper presents method to quantify surface characteristics small with well-defined surfaces based on thin-section CT images. The segmentation three-dimensional (3-D) nodule images are obtained by 3-D deformable approach. feature extraction algorithms designed characteristic parameters from using curvatures and ridge lines. Experimental results authors' method, applied patients...

10.1109/23.708321 article EN IEEE Transactions on Nuclear Science 1998-08-01

BACKGROUND In Japan, lung carcinoma is the leading cause of cancer-related deaths. Adenocarcinoma accounts for roughly half all carcinomas. Earlier detection expected to reduce mortality rates. Computed tomography (CT) provides higher contrast resolution and greater visualization chest compartments that are difficult view with radiography, such as mediastinum. CT further permits minute peripheral nodules. At present, several institutions research groups evaluating utility low dose spiral...

10.1002/1097-0142(20001201)89:11+<2485::aid-cncr28>3.0.co;2-t article EN Cancer 2000-12-01

Following phase I studies of docetaxel and cisplatin in patients with non-small-cell lung cancer, the recommended doses were different for elderly (> or = 75 years) non-elderly (< patients. To elucidate mechanism difference, pharmacokinetics investigated two II separately conducted patients.Twenty-seven 25 treated three weekly administrations every 4 weeks. Doses 20 35 mg/m(2) patients, respectively. All received cisplatin. The pharmacodynamics compared patients.There no differences between...

10.1200/jco.2004.10.163 article EN Journal of Clinical Oncology 2004-07-14
Coming Soon ...